Patient-derived xenografts and organoids model therapy response in prostate cancer. by Karkampouna, Sofia et al.
ARTICLE
Patient-derived xenografts and organoids model
therapy response in prostate cancer
Sofia Karkampouna 1,21, Federico La Manna 1,2,21, Andrej Benjak3, Mirjam Kiener1, Marta De Menna1,4,
Eugenio Zoni1, Joël Grosjean1, Irena Klima1, Andrea Garofoli5, Marco Bolis6,7,8, Arianna Vallerga6,7,
Jean-Philippe Theurillat6, Maria R. De Filippo1,5, Vera Genitsch9, David Keller10, Tijmen H. Booij 10,
Christian U. Stirnimann10, Kenneth Eng11, Andrea Sboner12, Charlotte K. Y. Ng 3, Salvatore Piscuoglio 5,13,14,
Peter C. Gray15, Martin Spahn16,17, Mark A. Rubin 18,19, George N. Thalmann1,20 &
Marianna Kruithof-de Julio 1,4,19,20✉
Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due
to lack of experimental models that mimic different disease stages. We describe an
androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft
tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and
organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors
BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1-like transcriptomic signature
and microsatellite instability, which occurs in 3% of advanced PCa and has never been
modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs
(BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds,
revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib)
were broadly effective on all PDX- and patient-derived organoids from advanced cases with
acquired resistance to standard-of-care compounds. This proof-of-principle study may pro-
vide a preclinical tool to screen drug responses to standard-of-care and newly identified,
repurposed compounds.
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Prostate cancer (PCa) is the second most commonly diag-nosed cancer type and the fifth leading cause of cancerdeath in men worldwide1. Androgen deprivation therapy
has been used to hamper tumor growth due to the hormone
sensitivity of the prostate. However, a subset of tumors will
acquire resistance and reoccur as castration-resistant prostate
cancer (CRPC). Novel classes of androgen inhibitors, such as
enzalutamide2 and abiraterone3, are used for CRPC cases, how-
ever acquisition of resistance and intratumor heterogeneity limits
their efficiency, thus compelling the use of drugs with different
mechanisms of action. The lack of available experimental models
of early stage, treatment-naive PCa is a major restriction in
preclinical PCa research.
Patient-derived xenografts (PDX) are used to address intra-
tumor characteristics and drug response since they model the
original tumor in a more representative manner than other
models such as two-dimensional cell culture4. Various PDX study
programs have evaluated the tumor take of various PDX models
of primary and metastatic PCa5–7, with the use of different
immunocompromised mouse strains, sites of implantations
(subrenal8, subcutaneous9, orthotopic5, intrafemoral10) and
grafted material (biopsies, cells, circulatory tumor cells11 and
patient-derived organoids (PDOs)9,12). Cohorts of available PCa
PDXs have expanded in recent years13–15. Overall, tumor take
proved to be consistently higher for PDXs from advanced and
therapy-resistant metastatic cases than for primary PCa, thus
underrepresenting early stage cases that can reflect disease pro-
gression events5,16,17.
Tumor-derived organoids recapitulate features of naturally
occurring tumors such as cellular phenotype, heterogeneity, drug
response, and overall complexity more efficiently than 2D cell
lines, while providing an alternative to animal models18,19. Sev-
eral studies have demonstrated that drug response in organoids
correlates with concomitant genomic profile and may predict
clinical outcome9,20,21. Large scale drug screening on primary
PCa organoids have not been yet performed, in contrast to CRPC
neuroendocrine PCa12, mainly due to the low proliferation rate of
PCa organoids and limited availability of material (e.g. needle
biopsies). The extent to which PCa PDX and organoids can
model key features of therapy resistance and drug response
remains unclear.
In this study, we describe the development of a PDX model
derived from a treatment-naïve soft tissue metastasis (PNPCa),
with androgen-sensitive characteristics. Molecular characteriza-
tion revealed distinctive genomic features including CHD1 and
BRCA2 mutations as well as high microsatellite instability (MSI-
H). To assess whether therapy resistance preexists in this
treatment-naïve PCa case, we developed a method for organoid
derivation that facilitates in vitro immunological assays and drug
screening. Using PDX organoids from three different models, we
established a pipeline for medium-throughput organoid drug
screen and implemented the use of a clinically relevant, near-
patient in vitro tool.
Results
Establishment of clinically relevant models for human PCa. We
have generated a PDX model from soft tissue metastasis maintained
in immunodeficient mice (PNmet) (Fig. 1a). Tissue morphology
(Fig. 1b, Supplementary Fig. 1a), presence of luminal markers PSA,
NKX3.1, AR, CK8 expression, and absence of CK5+ basal cells
(Fig. 1b, Supplementary Fig. 1b–d) indicated stable luminal epi-
thelial morphology among the primary TUR-P tumor (T1), the
PNmet, and PDX1–6 passages. Presence of prostatic ducts was
observed in the primary T1, PNmet, and PDXs, with a more dis-
tinctive ductal morphology in the PDXs (Fig. 1b, Supplementary
Fig. 1a). The PDX was established in two different immunocom-
promised strains, with and without testosterone supplementation
(Supplementary Fig. 1e). Flow cytometric analysis showed that
PNPCa PDX cells are positive for prostate-specific membrane
antigen (PSMA), E-cadherin (E-Cad), and Integrin α-6 (CD49f),
supporting the epithelial and prostatic origin of the tissue. In
addition, 37% of cells were CD44+, while a minor fraction stained
positively for CD36 (6%) and CD146 (1%) (Fig. 1c).
Tumor growth properties in response to androgen levels, were
addressed in vivo. The PDX (passage 6) was implanted
subcutaneously and received weekly testosterone injections,
reaching ~1000 mm3 volume by day 67 (Fig. 1d, Intact+ Testost,
black line). Surgical castration resulted in progressive tumor
regression, reaching non-palpable tumors by day 151 (Fig. 1d,
Castration, red line). Spontaneous, androgen-independent tumor
regrowth was not detected in castrated mice (up to 206 days post-
castration, Fig. 1d, day 273), including a setting of prolonged
androgen deprivation (up to 289 days post-castration; Supple-
mentary Fig. 2a, Prolonged Castrated+ testost, blue line).
Testosterone supplementation consistently induced tumor
regrowth in all castrated groups, with statistically significant
tumor burden after 42 days (Fig. 1d, Castrated+ Testosterone,
green line; day 231 p= 0.0005 (***), day 238 onwards p ˂ 0.0001
(****); Supplementary Table 1) and after 49 days (Supplemen-
tary Fig. 2a, Prolonged Castrated+ Testost, day 392 and 399 p=
0.0161, day 403 p= 0.0018) of androgen replacement, in the
castrated and prolonged castration groups, respectively.
At endpoint, tumors were subjected to histological and
transcriptomic analysis. Castration-induced reduction of epithe-
lial NKX3.1+, CK8+, AR+ glands (Fig. 1e; Castrated), which was
reversible upon testosterone administration (Fig. 1e; Castrated+
Testost). Castrated and androgen-replaced tumors were genomi-
cally homogeneous as they shared the majority of mutations with
the intact tumors (Fig. 1f, Supplementary Data 1). Whereas, after
prolonged castration, testosterone-replaced tumors acquired
additional mutations in JAK1 (p.Ala723Ser), AR (p.Thr878Ala),
and RET (p.Ser891Leu) genes (Supplementary Fig. 2b, Supple-
mentary Data 1). Analysis of different organs (liver, lung,
prostate, lymph node, femur, and tibia) at end point indicated
macroscopic foci on all lung tissues (Supplementary Fig. 2c), loss
of normal epithelial architecture in anterior prostate (Supple-
mentary Fig. 2d), human panCK cell infiltration of a lymph node
in one case (Supplementary Fig. 2d) and potential micrometas-
tases areas of scattered panCK+ (human specific) cells residing in
the bone (Supplementary Fig. 2e), although no apparent lesion
was detectable by X-ray (Supplementary Fig. 2f).
Principal component analysis (PCA) and unsupervised hier-
archical cluster analysis of RNASeq data (Fig. 1g and Supple-
mentary Fig. 3a) indicated high transcriptomic correlation among
tumors from intact and testosterone-replaced hosts, while tumors
from castrated hosts further diverged from the aforementioned
groups (Fig. 1g). Differential expression analysis revealed lower
expression of genes in metabolic pathways, mTOR, MYC, and AR
pathways in the Castrated group compared to the Intact tumor
groups (Fig. 1h). In particular, cluster analysis of AR pathway
showed the differential expression of multiple genes in the
castrated group, compared to both the intact and the androgen-
replaced groups (Supplementary Fig. 3b). The latter groups
shared similar transcriptomic profile and androgen sensitivity,
however, pathway analysis indicated that tumors from androgen-
replaced hosts had significant downregulation of cell cycle,
apoptosis and hypoxia-related pathways (NES ≤−1), and upre-
gulation of interferon response, protein secretion and androgen
response pathways (NES ≥ 1) (Supplementary Fig. 3c).
Androgen ablation by castration caused tumor regression,
whereas testosterone re-administration induced tumor regrowth,
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rendering the PNPCa an androgen-dependent, treatment-
naïve model.
Molecular analysis revealed genomic and transcriptomic sta-
bility among the PCa xenograft and organoid models. To
further explore the in vitro characteristics of the PDX tumor cells,
we developed an organoid culture method from bulk tumor tissue
that allows organoids to grow in suspension conditions, with no
requirement for extracellular matrix support (e.g. Matrigel). Two
previously established bone-metastatic PCa PDX models, BM1822
and LAPC923 were used for direct comparison with the PNPCa,
representing respectively, androgen-sensitive and androgen-
independent, advanced PCa models (Supplementary Fig. 4a, b).
Organoids derived from all investigated PDXs displayed budding
acinar and adenocarcinoma-like morphology, with the expression
of the luminal markers CK8, PSA and AR (Fig. 2a). Gene
expression of basal markers (CD49f/ITGA6, KRT5, KRT6) was
detected but less abundant than luminal ones (NKX3.1, AR,
CK18) in all organoid and PDX models (Supplementary Fig. 5a).
Tumorigenic potential of BM18 and LAPC9 organoids was
confirmed by subrenal grafting (Supplementary Fig. 4c–h) or
intraprostatic inoculation (Supplementary Fig. 4i–n). Organoid
viability was enhanced when cultured in dihydrotestosterone
(DHT)-supplemented organoid media (Fig. 2b).
Next, we analyzed the transcriptomic and genomic profiles of
PDX organoids and matched tissues, assessing its stability across
multiple samples (Supplementary Fig. 5b). PCA indicated that the
three PDX models were clearly distinct, while the matched PDX
tissues and organoids were highly similar (Fig. 2c). This was
further demonstrated by the high gene expression correlation
scores in PDX tissues and organoids, generated using the
developed culture system (Fig. 2d).
Fig. 1 Establishment of a novel androgen dependent, patient-derived xenograft from an early, treatment-naïve prostate cancer metastasis. a Scheme
of clinical history and patient-derived samples: primary tumor TUR-P (T1) and penile metastasis needle biopsies used to establish the PDX model (PNPCa)
and subsequent passages. Created with BioRender.com. b Histological morphology of primary TURP tumor, penile metastasis (PN met) from PCa and the
PDX passages 1 and 6 (PDX1, PDX6) derived from the metastasis needle biopsy implantation (PNPCa), as assessed by Hematoxylin and Eosin staining
(H&E). Scale bars 20 μm. Top to bottom panels: PSA protein expression. Scale bars 20 μm. Expression of AR (green), CK5 (red) assessed by
immunofluorescence, DAPI (blue) marks the nuclei. Scale bars 50 μm. Expression of NKX3.1 (green), CK8 (red) assessed by immunofluorescence. Scale
bars 50 μm. c Flow cytometry analysis of epithelial and prostate-specific marker expression in PNPCa PDX tissue. FcR-blocked PNPCa cells were stained
with antibodies against CD44, E-Cadherin, PSMA, CD49f, CD36, and CD146. d PDX tumor growth progression in time. Groups; 1. Intact tumors (collected
at max size, N= 2 independent animals), 2. Castrated (N= 5 independent animals), 3. Castrated followed by Testosterone re-administration (Castrated-
Testosterone independent animals) starting on day 189 (N= 4, N= 3 from day 203 to 252, N= 2 from day 252 to 273). Tumor scoring was performed
weekly by routine palpation; values represent average calculation of the tumors of all animals per group (considering N= 2 tumors, left L and right R of
each animal). Error bars represent SEM, calculated considering number of animals for each time point. Ordinary two-way ANOVA with Tukey’s multiple
comparison correction was performed. (*) p= 0.0105 day 217, (**) p= 0.0025 day 224, (***) p= 0.0005 day 231, (****) p≤ 0.0001 from day 238
onwards. e Top to bottom panels: Histological H&E staining of representative tumors from Castrated and Castrated-Testosterone hosts.
Immunofluorescence staining for AR and CK5, CK8, NKX3.1 and CK8, CD44, and Ki67. DAPI marks the nuclei. Scale bars 50 μm. f Genomic analysis of
PNPCa PDXs from intact and castrated animals, collecting samples at full regression (122 days) and after further testosterone replacement (84 days).
g Principal component analysis of the gene expression of the 500 most variable genes. h Gene set enrichment analysis plot of statistically significant
(adjusted p-value < 0.05) enrichment of HALLMARK pathways based on the differential expression analysis of the Castrated versus the Intact groups. NES,
normalized enrichment score.
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We next performed gene set enrichment analysis (GSEA) using
Hallmark and KEGG (C2 subset) gene sets (Supplementary Fig. 6,
log2FC (NES) ≥ | 1 |, FDR > 0.05). In all samples compared, we found
a significant upregulation of pathways involved in cell growth (E2F
targets, G2M checkpoint, DNA repair mechanisms, MYC targets),
metabolic activity (amino acid and fatty acid metabolism, oxidative
phosphorylation, protein secretion) and androgen-regulated path-
ways (androgen response, spermatogenesis). Downregulated path-
ways included epithelial plasticity (epithelial–mesenchymal
transition, adhesion molecules regulation), angiogenesis (angiogen-
esis, coagulation) and cellular interactions with immune system
(antigen presentation, interferons, and cytokines pathways).
We then assessed the genomic landscape of PNPCa PDX
model by whole exome sequencing (WES) (Fig. 2e, Supplemen-
tary Figs. 5b, 7a, b, Supplementary Data 2, Supplementary
Table 2). Copy-number analysis showed that PDX-derived
organoids retained the overall patterns of copy number altera-
tions (CNAs) of tissues (Supplementary Fig. 8a). Of the total
somatic non-synonymous mutations found, 51% were over-
lapping between all samples (Supplementary Fig. 8b, Supplemen-
tary Data 2). WES was additionally performed on the LAPC9 and
BM18 PDXs and organoids, which recapitulated the majority of
the somatic mutations detected in the matched PDX tissues and
organoids (Fig. 2e, Supplementary Fig. 7c, d, Supplementary
Fig. 2 Mutational landscape of PDX and PDX-derived organoids from PNPCa, and advanced androgen (in) dependent BM18 and LAPC9 models.
a Morphology of PNPCa, BM18, and LAPC9 PDX-derived organoids; brightfield images, whole mount immunofluorescence staining and 3D projection of
z-stack of organoids stained for PSA, AR, and CK8. DAPI marks the nuclei. Scale bars 50 μm. b Viability assay of organoids derived from PNPCa, BM18, and
LAPC9 tumor tissues and exposed to dihydrotestosterone (±DHT) for 48 h. Luciferase values (ATP release) are proportional to cell viability. Mean ± SD is
reported, N= 3,4 technical replicates per condition (PNPCa), N= 2,3 technical replicates per condition (BM18), N= 3,4 technical replicates per condition
(LAPC9). Two-tailed t-test, *p= 0.0161, p= 0.0277, **p= 0.0031. c Principal component analysis of the gene expression of the 1000 most variable genes
on PNPCa, BM18, and LAPC9 samples (PDX and PDX-derived organoids). d Correlation plots of gene expression between PNPCa PDX tissue (N= 3
biologically independent tumor samples) and organoids (N= 2 biologically independent organoid samples), BM18 PDX tissue (N= 2) and organoids (N=
2), LAPC9 PDX tissue (N= 2) and organoids (N= 2), p-values < 2.2e10−16. e Somatic mutation analysis of WES of tissue and organoids of PNPCa, BM18,
and LAPC9 PDX. Columns represent different samples, while rows represent selected genes categorized by pathway. Types of genetic aberrations are
indicated in different colors. Multiple types of mutations per gene are indicated with an asterisk. A–C indicate biological replicates. f Clonality analysis of
the PNPCa samples shown in e, inferred by PyClone. Only the largest clones (consisting of most variants) or those containing cancer genes are shown.
Numbers in circles indicate mean clonal prevalence, estimated for each sample. Mutations in cancer genes corresponding to each clone are reported on the
left and color-coded. Overall, most mutations (including those in cancer genes) occur at high prevalence in all samples (top two clones). WES, whole-
exome sequencing.
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Data 2, Supplementary Table 2). Frameshift mutations of high
impact detected in the BM18 model were in ATM, ZHFX3, and in
the chromatin modifiers KDM6A and ARID1A genes (Fig. 2e).
LAPC9 PDX returned an overall higher mutational burden,
which included a NKX3.1 deletion, along with frameshift
mutations in TP53, TMPRSS2, and PI3K and in genes of the
Wnt pathway (APC, CTNNB1) (Fig. 2e). Nearly all non-
synonymous somatic mutations in bona fide cancer genes were
preserved in the PNPCa models, including truncating mutations
in CHD1, ACVR2A, RNF43, APC, and BRCA2 (Fig. 2e,
Suppementary Fig. 7a). Three frameshift mutations in cancer
genes were lost in the PDX tumors: HGF, SPEN, and PIK3CG
(Fig. 2e, Supplementary Fig. 7a). No mutations in the AR gene
were identified, however mutations in the AR pathway-associated
gene UBE3A were detected, while mutations in PMEPA1 and
KDM3A were observed sporadically (Supplementary Fig. 7b). We
determined the cancer cell fraction (CCF) of the reported
mutations to determine their stability over PDX passaging and
organoid generation. Mutations with homogeneously high
prevalence in all samples (≥80% CCF) were found in CHD1,
APC, RNF43, and KMT2D (Supplementary Fig. 9). BRCA2 and
ACVR2A mutations were found in 60–90% CCF in P2, P3, P4,
and Org2 and in ≤20% CCF of T1 (Supplementary Fig. 9). We
next analysed the mutational variation of the sequenced PNPCa
samples by performing clonal analysis. Different clone dynamics
were detected for the most abundant clones and are reported in
Fig. 2f. Of relevance, CHD1 mutation was shared among all
subclones while two main subclones captured discrete subsets of
truncal mutations from the original primary tumor (T1) and
stably transmitted across PDX passages and organoid samples.
We compared gene expression of PNPCa samples to that of
genetically defined subgroups within the Cancer Genome Atlas
(TCGA). The PCA plot reports the variance of PCa cases with
CHD1 homozygous deletion (Supplementary Fig. 10a) or with
mutant FOXA1, SPOP, CHD1, ETS rearrangements (ERG, ETV1,
ETV4) (Supplementary Fig. 10b). We further cross-compared
those samples for their expression of genesets specific of different
signatures of PCa subtypes using single-sample gene-set enrich-
ment analysis (ssGSEA). While the signatures of ETS and SPOP/
FOXA1 subgroups were divergent from each other, all PNPCa
samples, clustered between the two categories (Supplementary
Fig. 10c) and closely to CHD1 homozygous-deletion group
(Supplementary Fig. 10a), in agreement with presence of a
truncating CHD1 mutation (Fig. 2d).
Additionally, we used transcriptomic analysis to compare the
PNPCa PDX to a subcohort of the LuCaP PDXs series13.
Unsupervised hierarchical cluster analysis placed PNPCa closely
with LuCaP-78 which, despite being classified as androgen-
sensitive adenocarcinoma-like PCa, was derived from a CRPC
patient already exposed to different lines of treatment, including
taxanes (Supplementary Fig. 10d). From a genomic standpoint,
LuCaP-23.1 and 145.2 contain heterozygous loss of BRCA2, a trait
associated with progression to CRPC24, while only LuCaP-147 is
reported to have a hypermutation profile associated to MSI-H25.
Thus, PNPCa PDX represents a model of treatment-naïve, early-
stage advanced disease, recapitulating features commonly found
in more progressed stages of PCa.
Functional testing of targeted treatments according to the
genomic profile of the PNPCa PDX and organoids. We next
characterized the functional implications of mutations in genes
linked to DNA stability, detected in the PNPCa models. In vitro
viability assays on irradiated PNPCa organoids showed a sig-
nificant reduction of viability already after 48 h compared to
control PNPCa organoids (Fig. 3a). Conversely, no difference in
viability was evident in irradiated organoids derived from BM18
or LAPC9, confirming the sensitivity of PNPCa to irradiation in
this experimental setup (Fig. 3a–c).
The mutational landscape of PNPCa primary tumor, PDX and
organoids was largely driven by mutational processes associated
with signatures of MSI (Fig. 3d), consistent with the observations
that this tumor had a higher mutation rate compared to other
PCa26, especially to those with an overall flat copy number profile
(Supplementary Fig. 8a) and an elevated proportion of small
indels27 (Supplementary Fig. 11a). We did not observe genomic
markers indicative of homologous recombination deficiency,
neither in terms of mutational signature (Fig. 3e) nor of large-
scale transitions28. The MSI status was further evaluated using the
MSIsensor algorithm29 and the Bethesda MSI test. MSIsensor
classified all the samples except the T1 tumor as MSI-H (Fig. 3e,
gray dotted line). Four out of the six loci of the Bethesda panel
were altered in the T1 tumor, confirming the tumor itself as MSI-
H (Supplementary Fig. 11b).
Considering that MSI score/defective mismatch repair
(dMMR) mechanism are used as biomarkers for PD-L1/PD-1
immunotherapy response30,31, and correlate with PD-L1 over-
expression32, we assessed the expression level of immune-related
markers and the overall immunomodulatory properties of PNPCa
organoids. Compared to the normal tissue N1, all the PDXs,
Org2, and the primary tumor showed a reduction of transcript
abundance of the major histocompatibility complex (HLA-A and
HLA-B) and of galectin-9, the main ligand of the inhibitory
receptor Tim-3. While the primary tumor, the soft tissue
metastasis, and the PDX-derived organoids showed a moderate,
epithelial-specific staining for PD-L1, PDX1, and PDX2 tissues
revealed a loss of expression of this marker in the epithelial
compartment (Fig. 3f). The increased level of expression of PD-L1
in the primary tumor compared to healthy tissue N1 was not
preserved in the PDX and in the organoid samples (Supplemen-
tary Fig. 11c, d).
We further assessed the expression of immune checkpoint
inhibitors after 48 h stimulation of PNPCa organoids with 50 ng/
ml IFN-γ. Treatment with IFN-γ was sufficient to significantly
evoke the upregulation of PD-L1 (p < 0.001) and galectin-9 (p=
0.0011), linked to immune evasion (Fig. 3g, Supplementary
Fig. 11e)33,34. However, as the molecular and histological data
could not provide a unitary picture for these markers, we further
investigated their functional role by co-culturing PNPCa
organoids with allogeneic CD3+ lymphocytes and mature
dendritic cells (mDC). Despite the upregulation of immune
checkpoint inhibitors at the molecular level, PNPCa organoids
did not modulate the proliferation, Treg polarization or PD-1
expression of CD3+ lymphocytes, even after 48 h pre-treatment
with IFN-γ (Fig. 3h–j). Overall, the current results do not support
the presence of an active immune evasion machinery in PNPCa
organoids.
Organoid drug response to standard-of-care and repurposing
of FDA-approved compounds on a medium-throughput
automated screen. We next implemented the PDX-derived PCa
organoid in a medium-throughput automated drug screening
pipeline. A total of 74 compounds, including routinely used PCa
standard-of-care drugs as well as different FDA-approved drugs
with indications for other cancer types were assayed, at multiple
concentrations (Supplementary Data 3). Overall, the tested
compounds targeted several distinct cellular processes and path-
ways, with a specific focus on signaling mediators including
growth factor receptors and androgen response.
Pre-screens were run for every PDX-derived organoid model to
optimize cell density, positive controls and time of drug exposure,
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according to a pipeline established using PNPCa organoids
(Supplementary Fig. 12a, b). Screens were run in at least three
independent replicates for each PDX model, validating each
replicate before data integration (Supplementary Fig. 12c, d).
Once automatically seeded, organoids were allowed to form for
48 h before adding the drugs; cell viability was assessed on-plate
after 48–72 h from initial drugs exposure (Fig. 4a).
PNPCa organoids showed resistance to the majority of the
tested drugs, however 14 drug compounds significantly reduced
their viability (Fig. 4b, Table 1, FDR < 0.05). The most effective
compounds targeted the AR pathway (enzalutamide), EGFR/
HER2 (afatinib, erlotinib, gefitinib), mTOR (rapamycin, temsir-
olimus), DNA replication (doxorubicin, daunorubicin, and
epirubicin), multiple tyrosine kinase pathways (sorafenib, pona-
tinib, sunitinib), c-Met (crizotinib), and Src (bosutinib). Perform-
ing the drug screen on multiple PCa PDX-derived organoid
models identified drugs that were both exclusively effective in
only one of the models as well as drugs broadly effective across all
tested PDX-derived organoids (Fig. 4b, Supplementary Fig. 13).
As expected, the amount of significant hits inversely correlated
with tumor aggressiveness. In particular, the androgen-sensitive
BM18 showed a specific sensitivity to taxanes, while the
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castration-resistant LAPC9 to mTOR inhibition by everolimus.
All models were sensitive to the tested anthracyclines (doxor-
ubicin, daunorubicin, and epirubicin) targeting DNA replication
and to the tyrosine kinase inhibitor ponatinib.
We next performed targeted pathway analysis to elucidate if
the pathways targeted by the screened drugs (e.g. mTOR, cell
cycle, AR, TKI targets; EGFR, FGFR, Jak/STAT, Src, PDGFRB)
were enriched in the PDX tissues as well as in their derived
Fig. 3 Correlation of genomic features and specific drug responses in organoid models. a–c Time course of ATP-mediated luminescence viability assay
following a single dose of 10 Gy irradiation on organoids derived from PNPCa (a), LAPC9 (b), and BM18 (c) PDX tumors. Mean ± SD is reported, N= 4 technical
replicates (t=0), N= 5 (for each of the t= 24, 48, 72, 96 h time points). Ordinary two-way ANOVA with Tukey multiple comparison test was performed.
****p < 0.0001. d Graph representing the percentage of contribution of specific mutagenic processes based on mutational signatures from PNPCa T1 (primary
tumor), PDX (passages P2-P4) and organoids (from P4 PDX). e MSI status based on MSIsensor algorithm (https://github.com/ding-lab/msisensor), score≥
3.5 indicates MSI-high. f PD-L1 IHC staining on positive control (placenta tissue), primary T1 tumor, PNmet needle biopsy, PDX1 and PDX2 of the PNmet, and
cytosmear of PDX-organoids. Images of representative areas per tumor sample are shown, relative to the positive control staining. g. Gene expression levels of
immune markers based on RT-qPCR results on PNPCa organoids RNA at baseline (black bars) and after 48 h exposure to IFN-γ (red bars). Mean ± SD is
reported, for VSIR N= 3, for PD-L1 N= 6, for PD-1, HLA-A, HLA-B N= 5 technical replicates, across two independent experiments. Two-tailed nested t-test.
****p < 0.0001. h–j MLR assay showing lymphocyte reactivity, Treg fraction and expression levels of surface PD-1, following coculture of PDX-derived PNPCa
organoids with T cells and allogeneic, monocyte-derived dendritic cells (DCs). Mean ± SD is reported, h N≥ 3 biologically independent samples per condition, N
= 2 mDC+ IFN-γ from four independent experiments; Mixed effects analysis (REML) with Geisser–Greenhouse’s correction and Dunnett’s post-hoc test was
performed. i N= 3 biologically independent experiments; one-way ANOVA with Dunnett’s correction for multiple comparisons was performed, j N= 2 per
condition from two biologically independent experiments. IHC, immunohistochemistry; MLR, mixed lymphocyte reaction.
Fig. 4 Drug sensitivity of organoids representing different PCa stages and identification of novel compounds for repurposing use, based on medium-
throughput organoid screens. a Scheme of experimental protocol for organoid drug screens. Created with BioRender.com. b Organoid drug screen
heatmap of log2 fold change viability values (over vehicle, for each PDX model) for PNPCa (N= 4 replicates), BM18 (N= 3), and LAPC9 (N= 3). Negative
log2 values (plotted in blue) indicate potential drug candidates with impact on cell viability. Staurosporine was used as positive control. Statistically
significant hits (FDR≤ 0.05) are indicated with an asterisk. Hits with a significant effect on at least one model are reported, listed in alphabetical order and
with effective dose indication on the right, in μM. Medium-throughput automated drug screens, using selected FDA-approved compounds, were performed
at Nexus Theragnostics platform. c Gene set enrichment analysis (GSEA) of PDXs tissue (PNPCa N= 3, BM18 N= 2, LAPC9 N= 2) and organoids (PNPCa
N= 2, BM18 N= 2, LAPC9 N= 2). Enrichment scores of selected Hallmark and KEGG (C2) pathways with FDR < 0.05 derived from differential expression
analysis of each group of samples vs. the non-carcinoma control tissue from PNPCa clinical sample (N1). NES normalized enrichment score. d In vivo
efficacy by ponatinib treatment in subcutaneous LAPC9 PDX model. Tumor-bearing mice received intraperitoneally (IP) daily injections of vehicle or
ponatinib (10mg/kg) and mean tumor size scoring (×100mm3) was plotted. Data are presented as mean ± SD, N= 10 independent tumor samples per
treatment group); Two-way ANOVA with Sidak correction. *p= 0.029 (day 18), p= 0.012 (day 20), p= 0.016 (day 22). Tumor weight was assessed at
endpoint and plotted as mean ± SD, N= 10 independent tumor samples per group; Two-tailed nested t-test. *p= 0.015. e Representative histology of
LAPC9 PDX tumors from the vehicle and ponatinib groups, collected at endpoint. HE, hematoxylin and eosin, Ki67 proliferation marker. Scale bars, 0.5 mm.
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organoids. A curated list of Hallmark and KEGG C2 pathways
significantly enriched in the PDX tissues and organoids is
reported in Fig. 4c. Differential expression and fGSEA analysis
indicated a significant upregulation of pathways linked to AR
signaling, DNA repair, mTOR signaling, and cell cycle progres-
sion across all PDX models and organoids, compared to normal
tissue (Fig. 4c, pathways with NES ≥ 1). Overall, pathway analysis
supported the results of drug screening on organoids and
highlighted the molecular correlation of tissue/organoids on
pharmacologically relevant pathways.
In order to validate the drug candidates, we performed drug
screens on ex vivo tissue slices from PNPCa, BM18, and LAPC9
PDX. We tested 13 compounds on PNPCa tissue slices including
12 of the effective compounds and docetaxel, which did not
significantly affect organoid viability in the PNPCa drug screen.
Of these, we were able to validate 11 out of the 13 tested
compounds (Supplementay Fig. 14a, b). We then tested a
selection of drugs, both effective and ineffective in the organoid
screening, on ex vivo tissue slices of LAPC9 and BM18 PDX. We
validated the effectiveness of 7 out of 11 tested compounds on
LAPC9 PDX and of 4 out of 5 tested compounds on BM18 PDX
(Supplementary Fig. 14c). Overall, the effective compounds
identified were part of three drug classes: anthracyclines, mTOR
inhibitors, and TKIs.
Among the multiple TKIs effective on the different organoid
models tested (Fig. 4b), ponatinib showed a clear dose-dependent
effect, both in the organoid and in ex vivo tissue slice assay, while
it has not been previously studied in the context of PCa. We
validated the in vivo efficacy of ponatinib on the most aggressive
PDX, LAPC9. The vehicle formulation was optimized for
intraperitoneal (IP) injection and matched the solubility profile
of vehicle DMSO (Supplementary Fig. 15a, b). Mice treated with
ponatinib had a significantly lower tumor burden compared to
controls already after 18 days from PDX implantation, resulting
in significantly lower tumor weight and volume in the treated
group at the end of the experiment (Fig. 4d, Supplementary
Fig. 15c, d). Moreover, treatment with ponatinib reduced the
average mouse weight loss seen in the control group and likely
ascribable to the effects of PDX growth (Supplementary Fig. 15e).
Histological morphology and quantification of Ki67 indicated no
significant treatment-dependent differences in proliferation rates
of the LAPC9 xenografts (Supplementary Fig. 15f, g). The
concordance of the in vivo data with the ex vivo and in vitro drug
screens is supporting the feasibility of an organoid-based drug
assay as a surrogate tool for in vivo response, therefore we further
investigated the efficacy of the identified compounds on patient-
derived material.
Defining a drug panel for therapy resistant PCa (PDXs and
patient-derived material) for routine organoid screens and
treatment decision. In order to develop a precision medicine
approach for PCa patients, we established PDOs from needle
biopsies of radical prostatectomy and metastatic specimens. As a
control for PDO formation efficiency, we sampled areas macro-
scopically unaffected by cancer in radical prostatectomy speci-
mens, based on the evaluation of board-certified pathologists. On
average, the matched control tissues formed fewer organoids
compared to samples from malignant PCa (Fig. 5a, “benign” and
“tumor”). PCa PDOs showed two main morphological pheno-
types in vitro: organoids with a more acinar or cystic morphology
and organoids with an adenocarcinoma-like phenotype (Fig. 5a,
“acinar” and “adenocarcinoma”). Although PDO cultures showed
both inter- and intra-patient morphological heterogeneity, each
PDO culture showed consistent morphology across passages.
Tumorigenic potential of PCa organoids was assessed by in vivo
intraprostatic injections (Supplementary Fig. 16, representative
cases).
Matched patients’ blood, bioptic tissue, and PDOs were subjected
to targeted RNA and DNA sequencing using a panel of clinically
relevant cancer-related genes and according to specimen abundance
(Fig. 5b–d, Supplementary Table 3). The demographic character-
istics of this cohort are included in Supplementary Table 4. In
54.5% of cases, the somatic mutations identified in PDOs were
matching those identified in the matched tissue (Fig. 5b, purple), in
27.3% of cases no genomic concordance/mutations in the organoids
were found (Fig. 5b, dark gray), and in 18.2% of the cases no
mutation was identified in both the organoids and the original
tissue (Fig. 5b, light gray), possibly due to sampling a no-tumor or
low-tumor area of the prostate. A binary heatmap plot details the
different mutations detected in the analyzed samples (Fig. 5c).
Comparison of transcriptomic profile of PCa bioptic tissues with
matched PDOs resulted in high correlation in the cases evaluated
(Fig. 5d, cases P61 and P62). Moreover, the analysis confirmed the
prevalence of luminal over basal markers in the analyzed PDOs
(Supplementary Fig. 17).
Of the effective drugs short-listed from the PDX-derived
organoids drug screening, we selected a panel of 13 most effective
compounds (based on statistical significance), together with 4
PCa standard-of-care compounds, to develop an in vitro, multi-
drug, PDO-based precision medicine assay. PDOs from three
advanced PCa cases as well as from two primary PCa cases were
screened with the assay (Fig. 5e). Confirmation of tumor content
was done either by genomic sequencing (Fig. 5c) or after
histopathological evaluation by certified pathologist. Normalized
viability scores for each assay are reported on the heatmap in
Fig. 5e and unsupervised hierarchical cluster analysis identified
compound classes with differential effectiveness. AR-interfering
drugs (abiraterone and enzalutamide) and docetaxel clustered
together with the controls, indicating overall a low efficacy on
PDOs. Drugs targeting mTOR (rapamycin, temsirolimus, ever-
olimus) and EGFR-targeting erlotinib significantly reduced
viability of PDOs only in some cases, showing differential
efficacy. A third group, consisting of anthracyclines, the mTKIs
ponatinib, bosutinib, and sunitinib, together with crizotinib, were
broadly effective, reducing PDO viability in most cases. From a
clinical standpoint, PDOs from patients receiving in their
treatment lines taxanes (case P89) or ADT (cases P80, P82,
P89, P133) confirmed resistance to these compounds in vitro with
the exception of cases P82 and P134, which were sensitive and
resistant, respectively, to enzalutamide despite undergoing (case
P89) or a lack of ADT treatment (case P134). Although larger
sample size would increase statistical robustness, this proof-of-
principle data endorses the applicability of a near-patient PDO-
based approach for personalized drug screening for PCa patients.
Discussion
In this study, we describe the establishment of a PCa PDX model,
from an early onset and treatment-naïve patient, representing a
critical stage of PCa between initial relapse and CRPC development.
We established organoid cultures from this and from more
advanced PCa PDXs (BM18, LAPC9), to develop an organoid-
based drug screening pipeline. We then further adapted organoid
cultures to patient-derived bioptic material, implementing a clini-
cally relevant, patient-tailored organoids drug screening assay.
PCa is generally a slow proliferating tumor with few key
mutations and genetic alterations commonly found in patients
such as TMPRSS-ERG, SPOP, FOXA1, PTEN35,36. SPOP is asso-
ciated with DNA repair errors and a higher number of genomic
rearrangements37. Although no SPOP mutation was identified in
the PNPCa, there was a higher transcriptomic correlation with
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SPOP-mutated cases compared to other subtypes and specifically
to the ERG-mutated ones: as characterized in previous studies,
SPOP mutations and ERG fusion are fundamentally mutually
exclusive38,39. Nevertheless, PNPCa PDX carries an inactivating
mutation in CHD1, an event frequently co-occuring with SPOP
mutations40 (15% of PCa cases show loss of heterozygosity for
CHD1) and driving PCa-specific growth in transgenic mice41.
The PNPCa model displays an heterozygous frameshift
mutation in the BRCA2 gene and high MSI, combining in one
model two of the four genomic subtypes of metastatic CRPC26.
Patients with germline BRCA2 defects have earlier disease onset, a
higher rate of 5-year metastatic progression and poor survival
compared to non-carriers42–44. PNPCa organoids exhibited sen-
sitivity to irradiation, a clinical treatment for patients harboring
BRCA2 mutations42. Tumors with BRCA1/2 defects and defective
DNA repair mechanism are particularly sensitive to DNA
damaging agents such as radiotherapy45 and to PARP inhibitors
such as olaparib, in use for breast and ovarian cancer46 and
currently in a phase III clinical trial for CRPC patients harboring
BRCA1/2 or ATM mutations (PROfound, NCT02987543).
To our knowledge, PNPCa is the only reported MSI-H case of
an early metastasis, retaining androgen sensitivity that has been
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modeled in vivo. Hypermutation and MSI are rare and sporadic
features of PCa47 that are associated with hereditary cancer
predisposition. Despite the high tumor mutational burden (18–20
mut/MB), no deleterious alterations were detected in key MMR
genes MSH2, MSH6, MLH1, or PMS2 in PNPCa samples. Albeit
rare, MSI-H features lacking a dMMR signature have been
clinically observed30,48. Other molecular mechanisms, such as
silencing of MLH1 gene promoter or other epigenetic regulations
may be responsible for the MSI-H status49,50.
In PCa, high MSI is associated with poorly differentiated
stage51,52 ranging from 1% of primary tumor cases to up to 12%
metastatic cases53. Among the patients with defined MSI-H/
dMMR molecular phenotype, ~50% respond to anti-PD-1/PD-L1
immunotherapy54. Given the lack of biomarkers for CRPC and
the higher MSI prevalence in metastatic cases compared to pri-
mary cases, screening of patients for MSI status during initial
diagnosis could determine whether anti-PD-1 treatment is the
optimum treatment option. However, the lack of pressure of an
immune system, common in both in vitro cultures and PDX
passaging, could mask the pathophysiological role of this axis.
Organoid medium composition and overall cultural techniques
were adapted from well-established and previously characterized
studies55,56, coherently with other recent research studies in the
field12,57. However, in order to develop a translational assay, we
eliminated extracellular matrix components to; increase drug
availability, facilitate drug screening throughput and elimination
of stromal cells. A drawback of this approach is that in our
established methodology, organoids were generally used within a
few passages. The preservation of high molecular correlation
between PDX tissue and PDX-derived organoids was preferred
over the opportunity to perform prolonged serial organoids
propagation. Moreover, the predominant luminal phenotype
observed in these PDX tumors was maintained in the organoid
culture models.
We cross-validated drug responses in a complementary ex vivo
assay on tissue slices, derived from the established PDXs based on
our previously developed methodology58. The findings from both
assays were similar, however organoid drug screenings are more
amenable to standardization and can be performed routinely, in a
shorter time frame and using limited amount of tissue from
patient-derived material.
The implementation of PCa organoids in translational assays
could facilitate the identification of effective therapies in non-
responders to anti-androgens or chemotherapy, especially if
repurposing drugs approved for other malignancies59. Differential
responses to AR-blockers in LAPC9 and BM18/PNPCa organoids
suggests that drug response correlates with individual tumor
phenotypes. PNPCa was the only model showing sensitivity to
EGFR-inhibitors: deregulation of EGFR signaling is found in a
subset of PCa cases, however EGFR inhibitors have showed
limited effectiveness60,61. Among the TKI inhibitors identified in
our screen, ponatinib emerged as broadly effective in metastatic
PCa PDX as well as in PDOs. While sorafenib and sunitinib have
been tested in phase II/III clinical trials for CRPC62,63, ponatinib
has not been yet investigated in PCa. Interestingly, both sorafenib
and ponatinib were identified as CRPC candidate compounds
based on a computational gene expression tool for drug identi-
fication64. and while its use in solid tumors is being currently
investigated65, it is approved mainly for patients with acute or
chronic leukemia (PACE Trial66) and with acquired resistance to
other TKIs67. When ultimately validated in vivo, ponatinib
resulted in significant tumor growth inhibition and a very good
tolerability for the duration of the experiment. These results
corroborate the potential of organoids-based assays on drug
screening applications in PCa.
We further developed a patient-derived organoid (PDOs)-
based drug screening on a limited cohort of PCa patients,
resulting in a descriptive, proof-of-principle study. PDOs
recapitulated in most cases the genomic alteration of the
matching tissues, both in metastatic and in primary lesions. In
some cases, however we could not detect mutations in the
PDOs or in both PDOs and matching tissues. This could be due
to the low (or no) tumor content of the initial biopsy as well as
to oncogenic mutations in regions outside those covered by our
targeted DNA analysis. The developed PDO-based drug assay
has an average duration of two weeks from initial organoid
formation until readout, a time frame compatible with clinical
decision-making. Individual inter-patient drug-sensitivity pro-
files, indicating the most effective compounds, even within the
same drug subclass, are suggested by the results of the perso-
nalized drug screenings. Addressing intra-patient reproduci-
bility was hampered due to the limited amount of material and
of matching tumor-adjacent tissue available. In line with the
high heterogeneity of PCa, the drug profiles correlated with
disease stage, however they did not always match with the
clinical history of the patient, highlighting the need to imple-
ment a near-patient assay. Our results highlight the applic-
ability of patient-derived organoid drug screenings to predict
clinical outcome21 and their correlation with genomic and
transcriptomic features of the primary tumor, as shown in
recent studies for lung68, gastrointestinal cancer21, hepatocel-
lular carcinoma69, and ovarian cancer70.
In summary, we presented a translational pipeline designed by
cross-platform analysis of an early onset and treatment-naïve PCa
xenograft model. The specific biologic and genetic landscape of
this model may provide insights into tumor growth, metastasis,
and drug resistance profile at an earlier stage of the disease.
Comparison of its drug response profile with those of more
advanced PCa PDXs allowed the generation of a highly transla-
tional tool for the evaluation of drug response in PDO, thus
supporting a precision medicine approach to clinical decision-
making.
Fig. 5 Patient-derived organoids (PDO) of multiple PCa cases preserve molecular signatures of the matched tissue and can be used to determine drug
sensitivity in vitro. a Representative brightfield images of PDOs from PCa (“tumor”) and from cancer unaffected control area (“benign”) from the same
patient (scale bar 100 μm). Representative images of PDOs with an acinar or cystic morphology and with an adenocarcinoma-like morphology (“acinar”
(scale bar 500 μm) and “adenocarcinoma” (scale bar 50 μm), respectively). b. Overview of the genetic profiles of N= 11 PCa tissue samples and matching
PDOs, determined by targeted sequencing of PCa-specific mutation panels. c Binary heatmap plot of the data presented in b. Rows represent samples (tissue
(T) and organoids (O) for each case), columns represent genomic mutations. d Correlation plots of gene expression between tissue and matched organoids
for PCa case 61 (left) and case 62 (right). Pearson correlation coefficient, r: 0.795 and 0.858, respectively. For both correlations, p value < 2.2e10−16.
e Results of PDO drug screen assay on three advanced PCa cases (P80, P82, P89) and two primary PCa cases (P133 and P134). Normalized viability z scores
are shown in the heatmap, with unsupervised hierarchical cluster analysis of the drugs. Asterisks indicate a significant reduction of viability compared to
vehicle (*p < 0.05). Statistical significance was determined by two-tailed t-test for abiraterone (vehicle EtOH) and by one-way ANOVA with Dunnett
correction for all remaining drugs (vehicle DMSO). Non-determined values are indicated in gray squares. Drug targets are indicated in the legend and
reported by a colored-coded square below each drug.
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Methods
Patient history. The established PDX was originated from a patient who presented
with primary PCa (Gleason 9) and underwent transurethral resection of the prostate
(TUR-P) procedure. After 6 months, biopsy sampling was performed and the patient
was diagnosed with a soft tissue metastasis; histopathology showed an infiltration of
an adenocarcinoma from the prostate, PSA 91 ng/ml. Orchiectomy was performed
directly after biopsy sampling, thus the tumor was androgen-dependent at the time of
collection. No biochemical relapse was observed up to 18 months since the diagnosis
(PSA < 1 ng/ml). All patients included in this study provided written informed con-
sent (Cantonal Ethical approval KEK 06/03 and 2017-02295).
Tumor sample preparation and xenograft surgery procedure. Needle biopsy
from soft tissue metastasis was collected in Dulbecco’s MEM (Gibco, 61965-026)
media containing primocin (InVivoGen). For xenograft implantation, needle biopsies
were implanted subcutaneously in male, NOD-scid IL2Rgammanull (NSG) mouse,
under aneasthesia (Domitor® 0.5mg/kg, Dormicum 5mg/kg, Fentanyl 0.05mg/kg).
Animal license BE 55/16 and BE 68/20. Weekly subcutaneous injections of testos-
terone propionate dissolved in castor oil (Sigma, 86541-5 G) were performed (2mg
per dosage, 25 G needle) starting 1 week after the surgery. For PDX passaging, serial
subcutaneous implantations of tumor pieces into new recipients (NSG or CB17 SCID
mice) was performed. Abiraterone acetate (Selleckchem, S2246) treatment was
administered once daily (i.p.) for 5 days per week over a duration of 4 weeks at 0.5
mmol/kg/d (5% benzyl alcohol and followed by 95% safflower oil solution).
DNA isolation from organoids and tissue samples. For DNA extraction from
organoids and tissue samples the DNeasy Blood and tissue kit (Qiagen, 69504) was
used. DNA from FFPE material was extracted Maxwell® 16 LEV RNA FFPE
Purification Kit (Promega, AS1260).
RNA isolation and RT-qPCR. RNA isolation from organoids was performed using
the PicoPure Arcturus (Thermo Scientific, KIT0204) kit method. Tissue RNA was
extracted using standard protocol of Qiazol (Qiagen) tissue lysis by TissueLyser (2
min, 20 Hz). Quality of RNA was assessed by Bioanalyzer (Agilent). RNA from
FFPE material was extracted using the Maxwell® 16 LEV RNA FFPE Purification
Kit (Promega, AS1260). Total RNA was used for cDNA synthesis using random
primers and RNAse H-MML-V reverse transcriptase first-strand cDNA synthesis
system (Promega AG, Dübendorf, Switzerland). For qPCR, cDNA (10 ng per
reaction) was amplified in a CFX Real Time Detection system (Bio-Rad, Cressier,
Switzerland) using SYBR Green Supermix reagent (Bio-Rad). Expression levels
were normalized to the transcripts of HPRT and ACTB. Primer sequences are
indicated in Supplementary Table 5.
Tissue dissociation and organoid culture. Tumor tissue was collected in Basis
medium (Advanced DMEM F12 Serum Free medium (Thermo Fisher Scientific,
12634010) containing 10 mM Hepes (Thermo Fisher Scientific, 15630080), 2 mM
GlutaMAX supplement (Thermo Fisher Scientific, 35050061), and 100 μg/ml Pri-
mocin (InVivoGen, ant-pm-1). After mechanical disruption the tissue was washed
in Basis medium (220rcf, 5 min) and incubated in enzyme mix for tissue dis-
sociation (collagenase type II enzyme mix (Gibco, 17101-015), 5 mg/ml dissolved
in Basis medium, DNase: 15 μg/ml (Roche, 10104159001) and 10 μM Y-27632-HCl
Rock inhibitor (Selleckchem, S1049). Enzyme mix volume was adjusted so that the
tissue volume does not exceed 1/10 of the total volume and tissue was incubated at
37 °C for 1–2 h with mixing every 20 min. After digestion of large pieces was
complete, the suspension was passed through 100 μm cell strainer (Falcon®, VWR
734-0004) attached to a 50 ml Falcon tube. Using a syringe rubber the tissue was
minced against the strainer and washed in 5 ml basic medium (220rcf, 5 min). Cell
pellet was incubated in 5 ml precooled EC lysis buffer (150 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA), incubated for 10 min, washed in equal volume of basis
medium followed by centrifugation (220rcf, 5 min). Pellet was resuspended in 2–5
ml accutase™ (StemCell Technologies, 07920), depending on the sample amount;
biopsies or tissue, and incubated for 10 min at room temperature. The cell sus-
pension was passed through 40 μm pore size strainer (Falcon®, VWR 734-0004),
and the strainer was washed by adding 2 ml of accutase on the strainer. Single cell
suspension was counted to determine seeding density, washed in 5 ml of basis
medium and spun down 220rcf, 5 min. Cell pellet was reconstituted in organoid
medium and seeded in ultra low attachment (ULA) plates; e.g. 30,000 cells per well
in 96-well plates with 100 μl media, 100,000 cells per well of 24-well plate with
750 μl media, 300,000–500,000 cells per well of 6-well plate (2 ml) (Corning, Costar
#3471, 3473, 3474). Organoid culture media contains the following reagents: Basis
medium containing 10 μM Y-27632-HCl (Selleckchem, S1049), 5% fetal calf serum
(Gibco #10270-106, LOT 42G7277K), 1× B-27 supplement (Thermo Fisher Sci-
entific, 17504044), 10 mM Nicotinamide (Sigma, N0636 100G), 500 ng/ml
Rspondin (Peprotech, 120-38), 1.25 mM N-acetyl-cysteine (Sigma, A9165), 10 μM
SB202190 (Selleckchem, S1077), 100 ng/ml Noggin (Peprotech, 250-38), 500 nM
A83-01 (Tocris, 2939), 10 nM DHT (Fluka Chemica, 10300), 10 ng/ml Wnt3a
(Peprotech, 315-20), 50 ng/ml HGF (Peprotech, 100-39), 50 ng/ml EGF (Peprotech,
AF-100-15), 10 ng/ml FGF10 (Peprotech, 100-26), 1 ng/ml FGF2 (Peprotech, 100-
18B), 1 μM PGE2 (Tocris, 2296). Media is prepared and kept at 4 °C for no longer
than 7 days.
Medium-throughput organoid drug screen at NEXUS personalized health
technologies automation platform
Compounds. A drug library was compiled based on predicted activity against PCa
(Selleck Chemicals, Houston, TX, USA) as 96-well format sample storage tubes
with drugs in 10 mM concentration. Using a Tecan EVO 100 (Tecan AG, Män-
nedorf, Switzerland), this drug library was aliquoted over 96-well plates (#651261,
Greiner Bio-One, Kremsmünster, Austria) and further diluted to yield stock plates
with a concentration of 10 mM, 1 mM, and 0.1 mM in DMSO (Sigma Aldrich, cat.
D8418). After aliquotting, plates were sealed under argon gas using an Agilent
PlateLoc (Agilent Technologies, Santa Clara CA, USA) with peelable aluminium
heat-sealing foil (Agilent, cat. 24210-001) for 1 s at 170 °C. An overview of the
purchased drugs and their known targets can be found in Supplementary Data 3.
Control molecules enzalutamide, docetaxel, and doxorubicin were purchased at
Sellechekchem (Lubio Science, Zürich, Switzerland, #S1250, #S1148, #S1208).
Staurosporine was purchased at Toronto Research Chemicals (Toronto, Canada,
#S685000).
Automated drug screening with PCa organoids. Automated screening procedures
were performed at NEXUS Personalized Health Technologies (ETH Zürich, Zür-
ich, Switzerland) using an automated screening platform (HighRes Biosolutions,
Beverley, MA, USA). PCa organoids of BM18, LAPC9, or PNPCa origin were
prepared and expanded from murine tumor tissue as for 5–7 days to allow orga-
noid formation using Costar ultra-low attachment plates (#3471, Corning, New
York, NY, USA). For the drug screens, organoids were dissociated into single cell
suspension by both enzymatic (TrypLE incubation) and mechanical separation (22
G needle), counted and seeded in ULA 384 well plates at appropriate cell density
for each tumor model; 3500 c/well (LAPC9, BM18) or 5000 c/well (PNPCa). Cells
were seeded 25 µL per well in 384-well flat-bottom ultra-low attachment plates
(#3827, Corning) using a BioTek EL406 with wide-bore 5 µL peristaltic pump
tubing (BioTek Instruments Inc., Winooski, VT, USA). After cell seeding, plates
were shaken for 2 min, incubated for 1 h at room temperature and subsequently
transferred to a 37 °C incubator with 95% humidity and 5% CO2. 48 h after cell
seeding, 96-well plates (#651261, Greiner Bio-One) containing 1000-times con-
centrated compound stock solutions at differing concentrations (10, 1, and
0.1 mM) in DMSO were centrifuged at 250rcf for 10 s (HiG 5000, BioNex Solutions
Inc., San Jose, CA, USA) and de-sealed using a Brooks Xpeel (Brooks Life Sciences,
Chelmsford, MA, USA) and subsequently diluted 1:125 in culture medium and
added to quadrant 1, 2, and 3 (respectively for 10, 1, and 0.1 mM stock plates) of
deepwell 384-well plates (#781271, Greiner Bio-One). DMSO-stock solutions of
control molecules (100% DMSO as negative control and as positive controls we
included 1000-times concentrated docetaxel [30 µM], enzalutamide [6 mM], and
doxorubicin [10 mM] for LAPC9 and BM18 organoids, or staurosporine [2.5 mM]
instead of docetaxel for PNPCa organoids) were added to plate quadrant 4. An
additional 1:1 dilution step was done prior to adding 20 µL of diluted drugs to the
cell culture plates (containing 20 µL cell suspension after correction for evapora-
tion). Compound dilutions were performed using automated liquid handling
equipment (Tecan AG, Männedorf, Switzerland) in technical triplicate (LAPC9
and BM18) or technical quadruplicate (PNPCa). A Schematic representation of the
compound dilution and addition procedure is shown in Supplementary Fig. 18a.
After compound exposure, compound DMSO stock plates were sealed under argon
gas using an Agilent PlateLoc as described above, and organoid culture plates were
transferred back to the 37 °C incubator with a 95% humidity and 5% CO2 atmo-
sphere. 48 h after compound exposure, a CellTiter-Glo 3D assay (#G9682, Pro-
mega, Madison, WI, USA) was used to measure ATP levels as a proxy for cell
viability. This assay is lytic and thus maximized readout from all cells composing
large organoid structures. The cell viability readout was performed according to
manufacturer’s instructions using the automation equipment. Briefly, 40 µL room-
temperature CellTiter-Glo 3D reagent was added per well to the assay plates using
an automated liquid handler (Tecan AG). Plates were subsequently shaken for
5 min on a BioTek EL406 and incubated in a temperature-controlled incubator at
22 °C for 25 min. After incubation, luminescence was measured using a Tecan
M1000 Pro plate reader (Tecan AG) with 1000 ms integration time. Results were
collected as spreadsheets and coupled to plate layouts.
Data have been normalized using the median of the negative control conditions
(DMSO 0.1%) and values have been log2 transformed (each plate with its own
internal negative control). For the statistical analysis the different plates have been
considered as replicates. p-value and FDR were calculated for all drugs after
removing DMSO and no-treated control conditions).
Material availability. All unique materials are readily available upon request to the
corresponding author.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the corresponding author. Sequencing data have been
deposited at the European Genome-phenome Archive (EGA), under accession number
EGAS00001004673 and EGAS00001004675. RNASeq related to Supplementary Fig. 10d
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were deposited at the ENA (European Nucleotide Archive/Arrayexpress) under accession
number E-MTAB-9656.
Received: 15 January 2020; Accepted: 19 January 2021;
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